SunTrust Banks (NYSE: STI ) is the holding company and publicly traded side of SunTrust Bank, one of the country's biggest regional banks. SunTrust primarily does three kinds of banking: consumer banking and private-wealth management; wholesale banking; and mortgage banking.
SunTrust puts up some impressive numbers, but there is at least one thing to watch out for. Thinking about investing in SunTrust? Here are seven things you need to know:
1. SunTrust is bigger than you think
Go out to the Federal Reserve's National Information Center, and you'll see that SunTrust is the country's 17th biggest bank-holding company, ahead of both American Express and Deutsche Bank. Size doesn't mean anything in and of itself, but used skillfully, size can help generate revenue and profit far beyond that of a smaller rival.
2. Great share-price performance over the past year
Since June 12 of 2012, SunTrust has returned 49.24% to its shareholders. It's true, investor darling Bank of America (NYSE: BAC ) has returned 83.79% over the past year, but that outsized return comes at the cost of greater balance-sheet and share-price volatility.
Top 5 Safest Stocks To Own For 2015: Raven Industries Inc.(RAVN)
Raven Industries, Inc., together with its subsidiaries, manufactures various products for industrial, agricultural, energy, construction, and military/aerospace markets primarily in North America. It operates in four segments: Applied Technology, Engineered Films, Aerostar, and Electronic Systems. The Applied Technology segment designs, manufactures, sells, and services precision agriculture products and information management tools enabling growers to enhance farm yields. Its products include field computers, application controls, GPS-guidance and assisted-steering systems, automatic boom controls, and yield monitoring planter controls, as well as an integrated real time kinematic and information platform called Slingshot. This segment sells its products to original equipment manufacturers, as well as through after market distributors. The Engineered Films segment produces rugged reinforced plastic sheeting for industrial, construction, geomembrane, and agricultural appli cations. It sells plastic sheeting to independent third-party distributors through its sales force. The Aerostar segment sells high-altitude research balloons and tethered aerostats for government and commercial research. It produces military parachutes, uniforms, and protective wear for the U.S. government agencies as a subcontractor; and other sewn and sealed products on a contract basis. The Electronic Systems segment provides electronics manufacturing services for commercial customers. It manufactures assemblies, including avionics, communication, environmental controls, and other products. The company was founded in 1956 and is headquartered in Sioux Falls, South Dakota.Advisors' Opinion:
- [By Monica Gerson]
Raven Industries (NASDAQ: RAVN) is estimated to report its Q4 earnings at $0.32 per share on revenue of $97.14 million.
Vail Resorts (NYSE: MTN) is expected to post its Q2 earnings at $1.87 per share on revenue of $471.16 million.
- [By Dividends4Life]
Memberships and Peers: MMM is a member of the S&P 500, a Dividend Aristocrat, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: General Electric Co. (GE) with a 3.1% yield, Raven Industries Inc. (RAVN) with a 1.6% yield and Carlisle Companies Inc. (CSL) with a 1.2% yield.
- [By victorselva]
General Electric has a current ratio of 10% which is lower than all the comps: 3M Company (MMM), Danaher Corp. (DHR), Carlisle Companies Incorporated (CSL), Koninklijke Philips N.V (PHG) and Raven Industries Inc. (RAVN).
5 Best Regional Bank Stocks To Watch Right Now: Senesco Technologies Inc (SNTI)
Senesco Technologies, Inc., incorporated on September 30. 1999, is engaged in utilize its eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for human therapeutic applications to develop approaches to treat cancer and inflammatory diseases. In agricultural applications, the Company has licensed applications of the Factor 5A, DHS and Lipase platforms to develop the productivity of fruits, flowers, vegetables, agronomic and biofuel feedstock crops through the control of cell death and growth in plants.
Human Therapeutic Applications
The Company has developed a therapeutic candidate, SNS01-T, an improved formulation of SNS01, for the potential treatment of multiple myeloma and non-Hodgkin B-cell lymplomas. SNS01-T utilizes the Company's Factor 5A technology and consists of two components, which include a DNA plasmid (pDNA), expressing human eIF5A containing a lysine to arginine substitution at amino acid position 50, (eIF5AK50R), and a small inhibitory RNA (siRNA). These two components are combined in a fixed ratio with a polymer, polyethyleneimine (PEI), which enables self-assembly of the DNA and RNA into nanoparticles with demonstrated enhanced delivery to tissues and protection from degradation in the blood stream. The Company has also demonstrated that the combination of lenalidomide and SNS 01-T performs better than either treatment alone in mouses xenograft models of human mantle cell lymphoma. The Company's human therapeutic research program, which consists of pre-clinical in-vitro and in-vivo experiments designed to assess the role and mode of action of Factor 5A in human diseases and a phase 1a/2b clinical trial.
The Company competes with Celgene, Inc., Takeda/Millennium, ONYX Pharmaceuticals, Inc., Amgen Inc., Janssen Biotech, Inc., Novartis AG, and Pharmacyclics, Inc.
The Company's agricultural research focuses on the discovery and develo! pment of certain gene technologies, which are designed to confer positive traits on fruits, flowers, vegetables, forestry species and agronomic crops. The Company's research and development initiatives for agriculture include develop and implement the DHS and Factor 5A gene technology in banana, canola, cotton, turfgrass, rice, alfalfa, corn, soybean and trees; and test the resultant crops for new beneficial traits such as increased yield, increased tolerance to environmental stress, disease resistance and more efficient use of fertilizer.
The Company competes with Mendel Biotechnology, Renessen LLC, Exelixis Plant Sciences, Inc., and Syngenta International AG.Advisors' Opinion:
- [By CRWE]
Today, SNTI has shed (-2.44%) down -0.0010 at $.0400 with�723,673 shares in play thus far (ref. google finance Delayed: 2:58PM EDT October 7, 2013).
Senesco Technologies, Inc. previously reported it has entered into a securities purchase agreement with certain investors to raise $1.725 million in gross proceeds through the sale of 69,000,000 shares of its common stock. The common stock was priced at $0.025 per share.
The offering is expected to close on or about October 2, 2013, subject to customary closing conditions. The net proceeds of the financing will be used primarily for working capital, research and development and general corporate purposes.
- [By Peter Graham]
At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:
5 Best Regional Bank Stocks To Watch Right Now: Five Prime Therapeutics Inc (FPRX)
Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company�� advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.
FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.
FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable disorders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.
FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor�� surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients��tumors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.Advisors' Opinion:
- [By Monica Gerson]
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares dropped 1.13% to $22.68 in pre-market trading after the company priced 3.41 million share offering at $22.00 per share.
- [By Monica Gerson]
Breaking newsAlcoa (NYSE: AA) is investing US$13 million to expand its wheel manufacturing plant in Europe, to meet growing demand for its lightweight, durable, low-maintenance aluminum truck wheels. To read the full news, click here. L & L Energy (NASDAQ: LLEN) announced today that its Special Independent Committee has appointed Mr. Nicholas Chen, Managing Partner at Pamir Law Group, to replace Mr. Mark Bartlett. To read the full news, click here. Five Prime Therapeutics (NASDAQ: FPRX) and Bristol-Myers Squibb (NYSE: BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform. To read the full news, click here. First Solar (NASDAQ: FSLR) on Sunday announced the completion of the 1.3MW(DC) solar photovoltaic (PV) power plant at Kitakyushu-shi. Powered by First Solar FS Series 3 Black PV modules, the plant will generate approximately 1,400 MWh of clean and safe solar electricity per year. To read the full news, click here.
Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
- [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]
Among the companies with shares expected to actively trade in Monday’s session are Keurig Green Mountain Inc.(GMCR), JA Solar Holdings Co.(JASO) and Five Prime Therapeutics Inc.(FPRX)
5 Best Regional Bank Stocks To Watch Right Now: SABMiller PLC (SBMRY)
SABMiller plc, incorporated on March 17, 1998, is a holding company, which has brewing and beverage interests across six continents. The Company together with its subsidiaries is engaged in the manufacture, distribution and sale of beverages. The Company is a brewer with more than 200 beer brands. The Company�� portfolio of brands includes international beers, such as Pilsner Urquell, Peroni Nastro Azzurro, Miller Genuine Draft and Grolsch, as well as local brands, such as Aguila, Castle, Miller Lite, Snow, Tyskie and Victoria Bitter. It is a bottler for the Coca-Cola Company in Africa and Central America. It operates in Latin America, Europe, North America, Africa, Asia Pacific, and South Africa.
The Company�� primary brewing and beverage operations cover six countries across South and Central America (Colombia, Ecuador, El Salvador, Honduras, Panama and Peru). The Company is brewer in Argentina, and it exports to Bolivia, Chile and Paraguay. It bottles soft drinks for The Coca-Cola Company in El Salvador and Honduras, and for Pepsico International in Panama.
The Company�� primary brewing operations cover eight countries: the Czech Republic, Hungary, Italy, Poland, Romania, Slovakia, Spain (Canary Islands) and the Netherlands. A further 16 countries, including Russia, Turkey and the Ukraine are covered in a strategic alliance with Anadolu Efes through brewing, soft drinks or export operations. The Company exports volumes to a further seven European markets, of which the largest are the United Kingdom and Germany.
The Company�� North America segment includes its 58% owned MillerCoors and 100% of Miller Brewing International and the its North American holding companies. The Company�� wholly owned Miller Brewing International business is based in Milwaukee, the United States and exports its brands to Canada and Mexico and throughout the Americas.
The Compa! ny�� brewing and beverage operations in Africa cover 15 countries. A further 21 are covered through a strategic alliance with the Castel group and it also has an associated undertaking in Zimbabwe. The Company bottles soft drinks for The Coca-Cola Company in 20 of its African markets (in alliance with Castel in 14 of these markets).
The Company�� partners with China Resources Enterprise, Limited in China. The Company is engaged in brewing business in India. The Company has operation in Vietnam and it exports to various markets, including South Korea and Singapore.
The Company�� South African Breweries (Pty) Ltd (SAB) is South Africa�� producer and distributor of lager and soft drinks. It also exports brands for distribution across Namibia. Its soft drinks division is bottler of products for The Coca-Cola Company. The Company has hotel and gaming interests through its associate, Tsogo Sun Holdings Ltd, a hotel and gaming group in South Africa.Advisors' Opinion:
- [By Rich Duprey]
Recently, Anheuser-Busch InBev (NYSE: BUD ) introduced in the U.S. its Stella Artois Cidre brand of cider as a means of siphoning off wine drinkers but also trying to steal some of Boston Beer's thunder. According to GuestMetrics, hard cider sales soared 70% in the first quarter, and it was largely on the back of Angry Orchard. Notably, MillerCoors, the joint venture between SABMiller (NASDAQOTH: SBMRY ) and Molson Coors (NYSE: TAP ) , also acquired cider maker Crispin last year.